The U.S. government is launching a demonstration program to make obesity drugs, such as GLP-1 receptor agonists, available to Medicare beneficiaries for the first time. This initiative, named the Bridge program, circumvents the statutory ban on Medicare coverage for obesity treatments by utilizing a temporary coverage model. The move follows resistance from private insurers regarding a previously proposed voluntary coverage structure.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.